FDA 执法报告 D-0037-2027 将 Apothecary Pharma 的 NAD+ 注射液召回列为 II 类

FDA drug recall enforcement report — D-0037-2027

Report issued: 2026-10-14. This is the enforcement report date, not the recall initiation date.

Scope: one classified drug product recall record; event_id may group multiple products. Unclassified records without recall numbers are outside this stream. This record is not a press release or a new enforcement finding.

The openFDA dataset is updated weekly. Report status is not a live recall status and must not be used to track the recall lifecycle. Other dates below retain their named meanings.

Complete official product record (including openFDA harmonized identifiers):

{

"address_1": "1913 Evans Rd",

"address_2": "N/A",

"center_classification_date": "20261008",

"city": "Cary",

"classification": "Class II",

"code_info": "Lot #: AP-202647, BUD 13-Oct-2026",

"country": "United States",

"distribution_pattern": "Nationwide within the United States",

"event_id": "99952",

"initial_firm_notification": "Letter",

"openfda": {},

"postal_code": "27513-2041",

"product_description": "Apothecary NAD+ Injection 200 mg/mL, 6 mL Sterile Multi-Dose Vial, Rx Only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC, 27513, NDC 85091-011-06.",

"product_quantity": "1 vial",

"product_type": "Drugs",

"reason_for_recall": "Lack of Assurance of Sterility",

"recall_initiation_date": "20260924",

"recall_number": "D-0037-2027",

"recalling_firm": "Apothecary Pharma LLC",

"report_date": "20261014",

"state": "NC",

"status": "Ongoing",

"voluntary_mandated": "Voluntary: Firm initiated"

}